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ABSTRACT: Dynamic alterations in cell surface glycosylation
occur in numerous biological processes that involve cell−cell
communication and cell migration. We report here imaging of
cell surface glycosylation in live mice using double click
chemistry. Cell surface glycans were metabolically labeled
using peracetylated azido-labeled N-acetylgalactosamine and
then reacted, in the first click reaction, with either a
cyclooctyne, in a Huisgen [3 + 2] cycloaddition, or with a
Staudinger phosphine, via Staudinger ligation. The second
click reaction was a [4 + 2] inverse electron demand Diels−
Alder reaction between a trans-cyclooctene and a tetrazine,
where the latter reagent had been fluorescently labeled with a
far-red fluorophore. After administration of the fluorescent
tetrazine, the bifunctional cyclooctyne-cyclooctene produced significant azido sugar-dependent fluorescence labeling of tumor,
kidney, liver, spleen, and small intestine in vivo, where the kidney and tumor could be imaged noninvasively in the live mouse.
■ INTRODUCTION
Glycosylation of cell surface proteins is involved in cell
differentiation, communication, and migration and is frequently
altered in disease, particularly in cancer.1 Several epithelial
tumors overexpress mucin glycoproteins, which can function as
scaffolds for various cancer-associated glycan epitopes2 and are
important biomarkers of tumor development, progression and
metastasis.3
The relative abundance and accessibility of cell surface
glycans and their changes in disease have made them attractive
targets for noninvasive imaging. Antibodies,4 peptides,5 boronic
acid-based probes,6 and lectins7 have been used for imaging
glycosylation in vivo. However, these imaging agents provide
only a snapshot view of tissue glycosylation, whereas metabolic
labeling with azido-sugars can, in principle, report on the
dynamics of glycan turnover. Metabolic labeling with azido-
sugars, in conjunction with click chemistry, has been used
previously for imaging glycans in mouse tissues, although the
click reaction or subsequent imaging was performed ex vivo.8,9
We reported recently the first demonstration of noninvasive
imaging of tumor sialylation in live mice10 based on labeling of
tumor glycans with an azido-sugar, followed by Staudinger
ligation with a biotinylated click reagent and subsequent
imaging with a fluorescent or radionuclide-labeled avidin probe.
Such a pretargeting approach has been widely used previously
in radionuclide imaging.11,12 However, the large size of the
avidin, which limited vessel permeability, precluded glycan
imaging in normal tissues. The aim of this study was to develop
small molecule click reagents that could be used to image azido-
sugar labeled glycans in any tissue in the living mouse.
Initially, we produced small molecule click probes, either by
direct conjugation of a Staudinger phosphine to a gadolinium
chelate, to generate an MRI contrast agent, or by conjugation of
a fluorophore to tetramethoxydibenzocyclooctyne (TMDI-
BO647),13 to generate a fluorescent agent. However, the
relatively slow reaction rate of azido-labeled sugars with
phosphines or cycloctynes meant that these reagents had to
be used at relatively high concentrations, which generated high
background signals and failed to give significant contrast in vivo
(see Figures S2 and S3 in Supporting Information). Therefore,
we developed a two-step labeling strategy (“double-click”) in
which the first click reagent is a bifunctional reagent, in which a
phosphine or cyclooctyne is conjugated to a trans-cyclooctene.
The imaging probe is then introduced in a second click reaction
between the trans-cyclooctene moiety and a tetrazine
conjugated to the imaging probe (Figure 1). Since this second
click reaction is 104−105 times faster than the first click
reaction, between the azido-labeled sugar and the phosphine or
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cyclooctyne, the imaging agent can be used at much lower
concentrations. This will lower background and improve image
contrast if the nonspecifically bound bifunctional agent is
washed out by the time the tetrazine imaging agent is
administered or if the trans-cyclooctene moiety is inaccessible
in the nonspecifically bound form. This strategy has the added
advantage that the imaging probe can be used at much lower
concentrations, which has a significant cost advantage in the
case of the fluorophore-labeled tetrazine and would minimize
radiation dose if a radiolabeled agent were used. Similar
tetrazine ligations, based on the inverse-electron-demand
Diels−Alder reaction, have been used recently for bioconjuga-
tion,14 for modifying live cell surfaces in combination with
cyclooctynes,15,16 although not in vivo, and as single probe in
vivo imaging agents.17
■ EXPERIMENTAL PROCEDURES
Cell Culture. Lewis lung carcinoma cells (LL2, from ATCC,
Teddington, UK) were grown in complete DMEM medium
(Dulbecco’s Modified Eagle medium) (Invitrogen, Paisley,
UK), supplemented with 10% fetal bovine serum (FBS) (PAA
Laboratories, Yeovil, UK) and maintained in 5% CO2, at 37 °C.
Probe Binding to Serum Albumin. BSA (Sigma-Aldrich,
Gillingham, UK) was incubated with either PHOS-TCO (3) or
TMDIBO-TCO (2) (see Figure 1) for 1 h at 37 °C in HBS
buffer (20 mM HEPES, 150 mM NaCl, pH 7.40). Tz-DyLight
(4; Figure 1) was added subsequently and reacted for a further
20 min. The directly conjugated probes, PHOS647, TMDI-
BO647, and DIFO6479 were incubated with BSA for 1 h at 37
°C. The mixtures were resolved by native gel electrophoresis
(Figure 2; 10% acrylamide, 0.8 M tricine, 1.2 M Tris, pH 8.3
(Expedeon, Harston, UK)). Tz-DyLight fluorescence (excita-
tion, λ: 630 nm; emission, λ: 680 nm) was detected following
illumination with 633 nm light using a Typhoon Trio scanner
(GE Healthcare, Hatfield, UK). Protein was detected after
Coomassie Blue staining (Instant Blue gel stain, Expedeon)
using an Image Scanner III scanner (GE Healthcare). Gel
densitometry was used to quantitate fluorescence intensity
using ImageJ software (National Institutes of Health, Bethesda,
MD, USA).
Cell Surface Azido-Glycan Labeling and Flow Cytom-
etry. LL2 cells were incubated for 24 h in complete DMEM
medium containing 50 μM of Ac4GalNAz (1; Figure 1) or
solvent vehicle (10% DMSO in HBS buffer). The medium was
then removed, and the cells were washed with warm PBS and
trypsinized (0.25% trypsin, 1 mM EDTA) (Invitrogen) at 37
°C for 5 min. Warm complete DMEM was added to inactivate
the trypsin. Cell suspensions were resuspended in cold FACS
buffer (1% FBS in HBS buffer) and reacted with TMDIBO-
TCO or PHOS-TCO (30 μM in FACS buffer containing 50
nM SYTOX Green (Invitrogen)) for 30 min at 37 °C. Tz-
DyLight (20 μM) was then added, and the cells were incubated
for a further 20 min. They were then washed three times with
cold FACS buffer, filtered through a 50-μm pore-size
membrane, and analyzed using a LSRII (BD Biosciences,
Oxford, UK) flow cytometer, using 20 000 events. Data analysis
was performed using FlowJo software (Tree Star, Ashland, OR,
USA). The population of interest (viable cells) was gated based
on high levels of NADH autofluorescence and low levels of
SYTOX Green staining. The far-red median fluorescence
Figure 1. Imaging cell surface glycosylation in vivo. Mice were injected i.p. daily for 3 days with peracetylated azido-labeled N-acetylgalactosamine
(Ac4GalNAz; 1), which is incorporated metabolically into N-azidoacetylgalactosamine units of cell surface glycans. The azido group in the glycan was
reacted in vivo with either TMDIBO-TCO (2) or PHOS-TCO (3), which were then reacted with Tz-DyLight (4) in vivo for subsequent
fluorescence imaging.
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intensity (MFI) of the viable cell population was then
determined. Data points were collected in triplicate.
Tumor Model and Metabolic Labeling in Vivo. BALB/c
female nude mice (aged 6−9 weeks) were purchased from
Charles River Laboratory (Kent, UK). LL2 cells (5 × 106) were
resuspended in ice-cold PBS and implanted (100 μL s.c.) in the
lower flank. After 7 days, mice were injected daily i.p. for 3 days
with a solution of Ac4GalNAz (300 mg/kg) in DMSO:PBS
(10:90%) or with the solvent vehicle alone. On day 11,
TMDIBO-TCO or PHOS-TCO or solvent vehicle
(DMSO:PBS, 6.7:93.3% or 0.3:99.7%, respectively) were
administered i.p. (67 or 3.3 μmol/kg, respectively). At 3 or
24 h after TMDIBO-TCO administration or 3h after PHOS-
TCO administration, Tz-DyLight (0.02 μmol/kg) was
administered i.v.
Imaging. Fluorescence imaging was performed using an
IVIS-200 camera (Perkin-Elmer, Waltham, MA, USA). Mouse
imaging in vivo was performed before and at 6 h, and 24 h after
intravenous administration of Tz-DyLight (Figure 3). Image
acquisition parameters: emission bandpass filter Cy5.5,
excitation filter Cy5.5, epi-illumination, small binning, aperture
range F1−F2, exposure 1−2 s; the field of view varied between
19.4 cm (in vivo) and 13.0 cm (ex vivo). All images were
normalized by dividing the fluorescence image by a reference
illumination image; this resulted in a unit-less fluorescence
efficiency scale, which represents the fractional ratio of emitted
photons per incident excitation photon, and which was
multiplied by a factor of 105 for ease of presentation. The
excitation and emission band-pass ranges were 615−665 and
695−770 nm, respectively. A far-red background band-pass
correction filter (580−610 nm) was also used to subtract
autofluorescence.
Probe biodistribution. Tissues were collected at 6 or 24 h
after the administration of Tz-DyLight. Tumor, hind limb
muscle, skin, kidney, spleen, small intestine, liver, heart, lung
and brain were harvested from animals that had been injected
with Ac4GalNAz (or solvent vehicle), TMDIBO-TCO and Tz-
DyLight. The tissues were kept briefly at 4 °C, weighed, imaged
Figure 2. Probe binding to serum albumin (a, b) and flow cytometric analysis of cell labeling (c−f). BSA was incubated with either PHOS-TCO
(lane 4, a, b) or TMDIBO-TCO (lane 5, a, b) and the TCO moieties were then reacted with Tz-DyLight. BSA was also incubated with the directly
conjugated probes, in which a Staudinger phosphine (PHOS647,13 lane 6), tetramethoxydibenzocyclooctyne (TMDIBO647,13 lane 7) or
difluorocyclooctyne (DIFO647,13 lane 8) were directly conjugated to a DyLight647 fluorophore. The BSA in the resulting reaction mixtures was
resolved on a native gel and stained with Coomassie Blue. The fluorescence from Tz-DyLight (a) and Coomassie Blue staining (b) were imaged. The
BSA monomer is indicated by the black arrow in (a). BSA oligomers frequently form under these conditions. Concentrations (a, b) are expressed in
μM. Lanes 2, 3, 9, 10, and 12 were not loaded. Lane 11 contained BSA (15 μM). Lewis lung carcinoma (LL2) cells were cultured in the presence or
absence of Ac4GalNAz for 24 h, washed and then incubated with either PHOS-TCO or TMDIBO-TCO and Tz-DyLight. Fluorescence histograms
of cells labeled with PHOS-TCO (c) or TMDIBO-TCO (d). Control groups (cells incubated in the absence of Ac4GalNAz): green (cells); orange
(cells + Tz-DyLight); blue (cells + PHOS-TCO or TMDIBO-TCO + Tz-DyLight); Test group (cells incubated with Ac4GalNAz): shaded red (cells
+ Ac4GalNAz + PHOS-TCO or TMDIBO-TCO + Tz-DyLight). Data in (e) are the mean ± SD (n = 3 replicate experiments/group, *p < 0.05, **p
< 0.005). Time course (f) of reaction of TMDIBO-TCO with Ac4GalNAz labeled LL2 cells.
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in the IVIS camera (Figure 4 and S1) and then fixed in neutral
buffered formalin (NBF: 4% formaldehyde in PBS) for 24 h,
prior to histological analysis. Tissue fluorescence was reported
as the ratio of the total fluorescence emission divided by the
wet weight of the tissue collected on necropsy, multiplied by a
factor of 105 for ease of presentation, and reported in arbitrary
units (Figures 4 and S1).
Histology and Fluorescence Microscopy. Immediately
after collection and fluorescence imaging, tissues were fixed
using NBF for 24 h at room temperature and transferred into
70% ethanol before paraffin embedding. Histological sections
(8-μm) were dewaxed and stained with either hematoxylin and
eosin (H&E) or mounted using aqueous medium (Prolong
Gold with DAPI; Invitrogen) for 16 h at room temperature.
Slides were then scanned in fluorescence mode (excitation, λ:
633 nm; emission, λ: 680 nm) using a Typhoon Trio scanner
(GE Healthcare) at 25-μm resolution.
■ RESULTS
Cell Labeling and Probe Synthesis. Cell surface glycans
were metabolically labeled using 1 (see Figure 1), a
peracetylated azido-labeled N-acetylgalactosamine (Ac4GalNaz)
that is incorporated into the core-0 of mucin-type O-linked
glycoproteins18 and also into glycosphingolipids, which are the
predominant glycans in lung tumors and in the murine small
cell lung cancer cells (LL2) used in this study.19 The azido-
labeled glycans were then reacted, in the first click reaction with
2, a bifunctional tetramethoxydibenzocyclooctyne conjugated
to a trans-cyclooctene (TMDIBO-TCO), in a Huisgen [3 + 2]
cycloaddition of the azido group with the cyclooctyne, or with
Figure 3. Planar fluorescence images of live mice bearing subcutaneous lung (LL2) tumors, injected i.p. with solvent vehicle (a, f) or Ac4GalNAz (1)
(b, g) daily for 3 days and then with TMDIBO-TCO (2) (a, b) or PHOS-TCO (3) (f, g). The fluorescent imaging agent, Tz-DyLight (4), was
injected i.v. 3 h (a−j) or 24 h (k-m) after injection of either TMDIBO-TCO or PHOS-TCO. Fluorescence images (λ, excitation: 647 nm; λ,
emission: 680 nm) were acquired at 6 and 24 h after the injection of Tz-DyLight. Black and white arrows in (a, b, f−g, k−m) indicate tumors and
kidneys, respectively. Data in (c−e, h−j) are mean ± S.E.M., N = 5/group; box plots represent median and 95% confidence intervals. Data shown in
(e) and (j) are the ratio of tumor mean fluorescence intensity (MFI) to the adjacent control (flank) tissue MFI at 24 h postinjection of Tz-DyLight.
Data in (n−o), in which Tz-DyLight was injected 24 h after injection of TMDIBO-TCO and images were acquired 6 h after injection of Tz-DyLight,
are the mean ± S.E.M., N = 3−4/group. Differences were considered significant when p < 0.05 (*) or p < 0.005 (**).
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3, a bifunctional trans-cyclooctene-phosphine (PHOS-TCO),
via Staudinger ligation of the azido group with the Staudinger
phosphine. The trans-cyclooctene groups were then reacted, in
a very fast20 second-click reaction involving a [4 + 2] inverse
electron demand Diels−Alder reaction, with 4, a fluorescently
labeled tetrazine (labeled with DyLight650; excitation λ: 652
nm; emission λ: 672 nm), whose fluorescence is detectable in
surface tissues in vivo. Both TMDIBO-TCO and PHOS-TCO
had a negatively charged lysine core to improve aqueous
solubility.
Comparison of Probe Binding to Serum Albumin.
Molecules, such as TMDIBO-TCO and PHOS-TCO, can bind
to serum albumins, removing them from the circulation21 and
conferring upon them the pharmacokinetic behavior of
macromolecular agents and thus restricting their tissue
access.13,22 The albumin-binding properties of TMDIBO-
TCO and PHOS-TCO were assessed by incubating them
with bovine serum albumin (BSA), and subsequently with Tz-
DyLight, and then separating the mixture on a native protein
gel. BSA was visualized by Coomassie blue staining (Figure 2b)
and Tz-DyLight by fluorescence imaging (Figure 2a). BSA
shows a characteristic ladder of oligomers on these gels.13 The
BSA-binding profiles were compared with those of TMDIBO
(TMDIBO647), a Staudinger phosphine (PHOS647), and a
difluorocyclooctyne (DIFO647),13 in which the fluorophore
was conjugated directly to these click reagents. TMDIBO-TCO
bound to BSA more strongly than PHOS-TCO (2.6 ± 0.3-fold)
(Figure 2) in agreement with previous studies.13 However, both
TMDIBO-TCO and PHOS-TCO showed less BSA-binding
(5.0 ± 0.6- and 3.8 ± 0.6-fold less, respectively) than their
directly fluorophore-conjugated counterparts (TMDIBO647
and PHOS647) and much less binding than DIFO647.13 The
higher binding of TMDIBO647 and PHOS647 cannot be
attributed to the presence of the fluorophore since the same
fluorophore was present in Tz-DyLight, which showed no
detectable binding to BSA (Figure 2).
Evaluation of Cell Labeling in Vitro. Next, we assessed
the reactivity of TMDIBO-TCO and PHOS-TCO for azido-
glycan detection in LL2 cells. Cells were cultured in the
presence or absence of Ac4GalNaz for 24 h, washed, and then
incubated with either TMDIBO-TCO or PHOS-TCO for 20
min followed by incubation with Tz-DyLight for 20 min. The
signal-to-background ratio (SBR) was considerably higher for
cells labeled with TMDIBO-TCO than with PHOS-TCO; 40 ±
1 and 1.7 ± 0.4 respectively (Figure 2c−e). These are
comparable to SBRs of 23.9 ± 0.8 and 3.3 ± 0.1, obtained
when the corresponding probes, in which the fluorophore was
attached directly to the phosphine (PHOS647) or cyclooctyne
(TMDIBO647),13 were used, indicating comparable reactivity
of the mono- and bifunctional reagents. The time course of the
reaction of TMDIBO-TCO with Ac4GalNAz-labeled cells is
shown in Figure 2f. Ac4GalNAz-labeled cells or controls were
collected at different times following the addition of TMDIBO-
TCO, incubated with Tz-DyLight for 20 min, washed and then
analyzed by flow cytometry. Cell viability was comparable and
>90% in both groups. Reaction of TMDIBO-TCO with the
azido-sugar labeled cells increased linearly relative to controls
for up to 6 h following addition of TMDIBO-TCO and then
plateaued thereafter. The decrease in cell labeling between 6
and 24 h can be explained by cell growth during this period,
when the cell number increased by ca. 70%.
Imaging Labeled Glycans in the Living Mouse. Mice
bearing subcutaneous LL2 tumors were injected i.p. daily, for
three days, with Ac4GalNaz or with solvent vehicle, and then
injected i.p., on day 4, with TMDIBO-TCO or PHOS-TCO
and 3 or 24 h later injected i.v. with Tz-DyLight. Fluorescence
images were acquired at 6 and 24 h postinjection of Tz-
DyLight. There was more fluorescence from the tumors and
kidneys of animals injected with Ac4GalNaz (Figure 3b,g),
when compared to controls injected with solvent vehicle
(Figure 3a,f), demonstrating glycan-dependent tissue labeling.
There was also considerably more fluorescence from these
Figure 4. Fluorescence microscopy of metabolically labeled glycans in mouse tissues. Tissues were collected post mortem, fixed for 24 h with 10%
formalin and embedded in paraffin. Histological sections were cut, dewaxed, and mounted, and cell nuclei were stained with DAPI. Fluorescence
images (columns 1 and 3, from left, in a) were collected at 25-μm resolution and compared with the corresponding H&E-stained sections (columns
2 and 4, from left, in a). The weight-corrected mean whole-organ fluorescence intensities (b, c), calculated from macroscopic images collected using
an IVIS 200 camera, are also shown for two panels of mouse tissues (b, c). The times allowed for TMDIBO-TCO and Tz-DyLight clearance from
the body, prior to ex vivo imaging, were 3 and 24 h respectively in (b) and 24 and 6 h respectively in (c). Data in (b, c) are mean ± SEM. Differences
between groups (b, c) were considered significant when *P < 0.05 (N = 4−7/group). Error bars in (b, c) lie within the chart bars when not visible.
Scale bars (a): 50 μm.
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tissues in animals injected with TMDIBO-TCO (>2-fold) when
compared to those injected with PHOS-TCO (Figure 3b,g; c,h;
d,i). These results were confirmed by ex vivo measurements
(Figure 4 and Figure S1). These data are qualitatively in
agreement with the differences in LL2 cell labeling observed in
vitro (Figure 2c−e). Better labeling with TMDIBO-TCO as
compared to PHOS-TCO was confirmed by measurements of
the tumor-to-flank fluorescence ratios (Figure 3e,j). These
ratios for control animals (injected with solvent vehicle instead
of Ac4GalNaz) are a measure of nonspecific probe accumu-
lation in the tumor interstitial space. This tumor-to-flank ratio
in vivo, 24 h post injection of the probe was 1.5 ± 0.2 in the
animals used here as compared to a much higher value of 2.3 ±
0.4 observed previously with NeutrAvidin as the imaging
probe.10 The lower ratio reflects presumably the much smaller
size of the probes compared to NeutrAvidin, which will
facilitate their washout, and their lower protein binding when
compared to TMDIBO647 (Figure 2). The higher glycan
labeling with TMDIBO-TCO as compared to PHOS-TCO
(Figure 3) is most likely due to its greater aqueous solubility,
which meant that it could be administered at higher
concentrations (67 μmol/kg for TMDIBO-TCO versus 3.3
μmol/kg for PHOS-TCO), and also its greater reactivity
toward azido-labeled glycans (23.2 ± 1.0-fold; Figure 2e). The
fluorescently labeled imaging probe Tz-DyLight was used at
0.02 μmol/kg. Extending the clearance time for TMDIBO-
TCO from 3 to 24 h decreased the background fluorescence by
∼50% and thus increased the change in the signal-to-
background ratio (Figure 3k−o), from +95% (Figure 3c, 6 h)
to +130% (Figure 3n) for tumors and from +120% (Figure 3d,
6 h) to +145% (Figure 3o) for kidneys. In control animals
injected with TMDIBO-TCO and Tz-DyLight, in which the
TMDIBO-TCO was allowed to clear for only 3 h before
injecting the Tz-DyLight, the background was ∼2 au (−/+/+,
Figure 3c,d, 6 h), whereas with a clearance time of 24 h the
background was ∼1.0 au for both control groups (−/+/+ and
−/−/+, Figure 3n,o).
Imaging Tissue Glycans ex Vivo. The limited depth
penetration of the fluorescence emission meant that we were
only able to image superficial glycan-labeled tissues in vivo
(tumor and kidney), however this could easily be extended to
deeper tissues by using an imaging modality with greater tissue
penetration, such as radionuclide imaging.10 In order to
determine the range of tissues that were labeled we imaged
excised tissues at high-resolution (Figure 4a). There was
significant labeling of tumor, kidney, small intestine, spleen and
liver (Figure 4b,c). Within the tumors, areas rich in tumor cells
showed 3.1 ± 0.2-fold greater fluorescent labeling (Figure 4a-
TC), whereas areas of dense neutrophil infiltration, which have
been reported previously in LL2 tumors and in human non
small cell lung carcinoma,23,24 showed only low levels of
fluorescence. Spleen (Figure 4a-SC) showed very intense
labeling of the red pulp (12.7 ± 0.7-fold more than control,
Figure 4a-SA), which was likely associated with high levels of
terminal N-acetyl-D-galactosamine residues present in retic-
ulocytes25 and low labeling of the white pulp, which may reflect
the fact that nude mice lack both mature B and T lymphocytes.
Small intestine (Figure 4a-IC) showed intense fluorescence
located predominantly on the luminal aspect, possibly
associated with goblet cells, which are rich in terminal N-
acetyl-D-galactosamine in cell surface mucins.26,27 Kidney
(Figure 4a-KC) showed an intense renal cortical signal (8.6
± 0.6-fold more than control, Figure 4b-KA), which may be
associated with S3 proximal tubules or collecting ducts, which
have high levels of N-acetyl-D-galactosamine.28 Liver (Figure
4a-LC), which is an important site for N-acetyl-D-galactosamine
protein O-glycosylation,29 showed intense fluorescence (1.6 ±
0.2-fold more than control, Figure 4a-LA) within portal tracts,
central vein and in the main hepatic tissue. Brain and heart
tissue were unlabeled. Brain glycans have been shown
previously not to label with azido-sugars9 and observation of
heart tissue labeling with a different azido-sugar to that used
here10 suggests the failure to detect labeling may be due to
limited incorporation of Ac4GalNaz into heart tissue glycans. A
longer TMDIBO-TCO clearance time of 24 h vs 3 h
substantially reduced background labeling and thus generated
considerably more contrast (10-, 6-, 2.3-, and 1.6-fold more
contrast for tumor, spleen, small intestine and liver respectively;
see Figure 4b vs 4c). Further work is required to determine the
extent to which probe pharmacokinetics and vessel permeability
affect the extent of tissue labeling.
■ DISCUSSION
Click chemistry has been used previously for labeling and
imaging cell surface glycans in developing zebrafish30 and
Caenorhabditis elegans.31 In the mouse, tissues including
splenocytes, intestine, kidney, heart, and liver have been
glycan-labeled. Initially, the click reaction was performed ex
vivo, on isolated splenocytes or on protein extracts of the
various tissues,8 and the labeled click reagent was then detected
by flow cytometry or Western blotting. Subsequently, the click
reactions have been performed in vivo, although detection of
azido-labeled glycan that had reacted with the click reagent was
again performed ex vivo.9 Biocompatible, small molecule, and
fast-reacting click reagents that can be used to image glycan
labeling in vivo in the mouse have yet to be described. We
showed previously that we could detect and image azido-sugar
labeling of tumor glycans in vivo using a phosphine-biotin
probe, in which the biotin was detected, following Staudinger
ligation between the azido-sugar and the phosphine, using a
NeutrAvidin imaging probe that had been tagged with either
fluorescent or radionuclide labels.10 However, the large size of
the NeutrAvidin meant that it could not access normal tissues,
and imaging was restricted largely to tumor glycans. The large
size of the probe also resulted in relatively high levels of
nonspecific tumor retention via the enhanced permeability and
retention (EPR) effect.32 We have since attempted direct
conjugation of a Staudinger phosphine to a gadolinium chelate,
as a contrast agent for MRI; however, this probe generated a
high background signal on MR images acquired in vivo and
failed to give significant contrast (Figure S2). A fluorophore-
labeled tetramethoxydibenzocyclooctyne (TMDIBO),13 which
has ca. 40-fold faster reactivity with azido-sugar labeled cells in
vitro than the Staudinger phosphine,13 showed ca. 3-fold higher
non-azido-sugar dependent retention of the probe in tumors, in
comparison with surrounding tissue, at 24 h post injection. This
nonspecific tumor retention, which is much higher than that
observed with the probes used here (ca. 1.0−1.5-fold; Figure
4), can be explained by its higher protein binding (Figure 2),
which again impaired the development of significant contrast in
vivo (Figure S3).
We have described here a double click labeling approach for
imaging cell surface glycans in mouse tissues in vivo, which
employs small molecule reagents that can access normal tissues
and which show good clearance properties. In the first bio-
orthogonal click reaction, TMDIBO or PHOS groups react
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with an azido-labeled sugar that has been incorporated into cell
surface glycans, and then, in a second click reaction, the TCO
group reacts with a fluorescently labeled tetrazine (Tz-
DyLight). We have shown that these reagents will fluorescently
label tumor, spleen, kidney, liver, and small intestine in vivo,
although only tumor and kidney tissue could be imaged in vivo
due to the limited tissue penetration of light in the far-red
range. In tumors and kidney, we showed that TMDIBO-TCO
was much better at labeling glycans than PHOS-TCO (Figure
4). This is most likely due to its greater aqueous solubility,
which means that it can be administered in vivo at higher
concentrations, and also its greater reactivity toward azido-
labeled glycans (∼20-fold; Figure 3). The fluorescently labeled
imaging probe, Tz-DyLight, could be used at much lower
concentrations since the [4 + 2] Diels−Alder reaction between
TCO and tetrazine is very fast (k2 = 13090 M
−1 s−1 measured
in PBS buffer at 37 °C16) when compared to the [2 + 3]
cycloaddition between the azido-sugar and the TMDIBO (9.4
× 10−2 M−1 s−1 in MeOH).9 Moreover, reaction of the tetrazine
in Tz-Dylight with a TCO group increases the far-red
fluorescence of DyLight647, which in the case of TMDIBO-
TCO increased by 60% (see Supporting Figures S4 and S5). All
three reagents showed relatively low protein binding (Figure
2), which facilitated their clearance from the body and thus
produced relatively rapid tissue contrast. In this study,
TMDIBO-TCO or PHOS-TCO were administered 3 or 24 h
before the Tz-DyLight and the animals were then imaged at 6
and 24 h after Tz-DyLight administration. Increasing the
clearance time for the “double click” probe TMDIBO-TCO
from 3 to 24 h substantially reduced the background and thus
generated considerably more glycan-dependent contrast, both
in vivo (Figure 3) and ex vivo (Figures 4 and S1), particularly in
tumor tissue, where the contrast was increased by ∼40% in vivo
and ∼10× ex vivo. Image contrast in tumor and kidney,
however, was not improved on increasing the clearance time for
Tz-DyLight from 6 to 24 h; in fact, there was a slight decrease
in image contrast by 24 h (Figure 3).
■ CONCLUSIONS
In summary, the bifunctional probes described here provide a
set of chemical tools with which to image tissue glycosylation in
vivo. These probes represent a significant advance over those
described previously in that they show much lower levels of
nonspecific albumin binding than the corresponding mono-
functional probes and also better tissue penetration and lower
levels of nonspecific retention in vivo than a macromolecular
imaging probe used previously.10 These characteristics led to
glycan-dependent labeling of normal tissues in vivo as well as
better image contrast in tumors.
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